Advertisement

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, Victoria Wang, Neil E. Kay, Curtis A. Hanson, Susan M. O'Brien, Jacqueline C Barrientos, Harry P. Erba, Richard M. Stone, Mark R. Litzow and Martin S. Tallman